ID

36650

Beschreibung

A Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least Two Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT02409368

Link

https://clinicaltrials.gov/show/NCT02409368

Stichworte

Versionen (2)
  1. 28.05.19 28.05.19 -
  2. 28.05.19 28.05.19 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

28. Mai 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Non-Small Cell Lung Cancer NCT02409368

Englisch

Eligibility Non-Small Cell Lung Cancer NCT02409368

1 Formulare  
Criteria
Beschreibung

Criteria

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
easter cooperative oncology group (ecog) status: performance status (ps) 0-1 & ps 2
Beschreibung

ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
subjects with histologically or cytologically-documented sqnsclc
Beschreibung

Squamous non-small cell lung cancer

Datentyp

boolean

Alias
UMLS CUI [1]
C4509816
subjects must have experienced disease progression or recurrence during or after both a platinum doublet-based chemotherapy regimen and at least 1 additional systemic therapy
Beschreibung

Disease Progression | Recurrence | Status post Chemotherapy Platinum-Based Double | Status post Systemic therapy Quantity

Datentyp

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2]
C0034897
UMLS CUI [3,1]
C0231290
UMLS CUI [3,2]
C0392920
UMLS CUI [3,3]
C1514162
UMLS CUI [3,4]
C0205173
UMLS CUI [4,1]
C0231290
UMLS CUI [4,2]
C1515119
UMLS CUI [4,3]
C1265611
subjects must have evaluable disease by ct or mri per response evaluation criteria in solid tumors (recist 1.1) criteria
Beschreibung

Evaluable Disease CT | Evaluable Disease MRI

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1516986
UMLS CUI [1,2]
C0040405
UMLS CUI [2,1]
C1516986
UMLS CUI [2,2]
C0024485
subjects with treated or asymptomatic cns metastases
Beschreibung

CNS metastases Treated | CNS metastases Asymptomatic

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C1522326
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231221
prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
Beschreibung

Palliative course of radiotherapy Completed

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0475092
UMLS CUI [1,2]
C0205197
males and females, ages 18 or older
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with untreated, symptomatic cns metastases
Beschreibung

CNS metastases Untreated | CNS metastases Symptomatic

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0332155
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0231220
subjects with carcinomatous meningitis
Beschreibung

Meningeal Carcinomatosis

Datentyp

boolean

Alias
UMLS CUI [1]
C0220654
subjects with active, known or suspected autoimmune disease
Beschreibung

Autoimmune Disease | Autoimmune Disease Suspected

Datentyp

boolean

Alias
UMLS CUI [1]
C0004364
UMLS CUI [2,1]
C0004364
UMLS CUI [2,2]
C0750491
subjects who received prior therapy with anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody (including ipilimumab or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized bms clinical trial for nivolumab or ipilimumab
Beschreibung

Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody | ipilimumab | Monoclonal Antibodies | Targeted Therapy T cell costimulation | Study Subject Participation Status | nivolumab

Datentyp

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C4289970
UMLS CUI [3]
C4289971
UMLS CUI [4,1]
C1705357
UMLS CUI [4,2]
C0003250
UMLS CUI [5,1]
C0214721
UMLS CUI [5,2]
C0003250
UMLS CUI [6]
C4289973
UMLS CUI [7]
C1367202
UMLS CUI [8]
C0003250
UMLS CUI [9,1]
C2985566
UMLS CUI [9,2]
C1622572
UMLS CUI [10]
C2348568
UMLS CUI [11]
C3657270
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Non-Small Cell Lung Cancer NCT02409368

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Item Group
C1512693 (UMLS CUI)
ECOG performance status
Item
easter cooperative oncology group (ecog) status: performance status (ps) 0-1 & ps 2
boolean
C1520224 (UMLS CUI [1])
Squamous non-small cell lung cancer
Item
subjects with histologically or cytologically-documented sqnsclc
boolean
C4509816 (UMLS CUI [1])
Disease Progression | Recurrence | Status post Chemotherapy Platinum-Based Double | Status post Systemic therapy Quantity
Item
subjects must have experienced disease progression or recurrence during or after both a platinum doublet-based chemotherapy regimen and at least 1 additional systemic therapy
boolean
C0242656 (UMLS CUI [1])
C0034897 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
C1514162 (UMLS CUI [3,3])
C0205173 (UMLS CUI [3,4])
C0231290 (UMLS CUI [4,1])
C1515119 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
Evaluable Disease CT | Evaluable Disease MRI
Item
subjects must have evaluable disease by ct or mri per response evaluation criteria in solid tumors (recist 1.1) criteria
boolean
C1516986 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
C1516986 (UMLS CUI [2,1])
C0024485 (UMLS CUI [2,2])
CNS metastases Treated | CNS metastases Asymptomatic
Item
subjects with treated or asymptomatic cns metastases
boolean
C0686377 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231221 (UMLS CUI [2,2])
Palliative course of radiotherapy Completed
Item
prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration
boolean
C0475092 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
Age
Item
males and females, ages 18 or older
boolean
C0001779 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
CNS metastases Untreated | CNS metastases Symptomatic
Item
subjects with untreated, symptomatic cns metastases
boolean
C0686377 (UMLS CUI [1,1])
C0332155 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
Meningeal Carcinomatosis
Item
subjects with carcinomatous meningitis
boolean
C0220654 (UMLS CUI [1])
Autoimmune Disease | Autoimmune Disease Suspected
Item
subjects with active, known or suspected autoimmune disease
boolean
C0004364 (UMLS CUI [1])
C0004364 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Prior Therapy | Anti-PD1 Monoclonal Antibody | Anti-PD-L1 Monoclonal Antibody | PD-L2 Monoclonal Antibody | CD137 Monoclonal Antibody | Anti-CTLA-4 Monoclonal Antibody | ipilimumab | Monoclonal Antibodies | Targeted Therapy T cell costimulation | Study Subject Participation Status | nivolumab
Item
subjects who received prior therapy with anti-pd-1, anti-pd-l1, anti-pd-l2, anti-cd137, or anti-ctla-4 antibody (including ipilimumab or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways) or who have previously taken part in a randomized bms clinical trial for nivolumab or ipilimumab
boolean
C1514463 (UMLS CUI [1])
C4289970 (UMLS CUI [2])
C4289971 (UMLS CUI [3])
C1705357 (UMLS CUI [4,1])
C0003250 (UMLS CUI [4,2])
C0214721 (UMLS CUI [5,1])
C0003250 (UMLS CUI [5,2])
C4289973 (UMLS CUI [6])
C1367202 (UMLS CUI [7])
C0003250 (UMLS CUI [8])
C2985566 (UMLS CUI [9,1])
C1622572 (UMLS CUI [9,2])
C2348568 (UMLS CUI [10])
C3657270 (UMLS CUI [11])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video